in Newswire Published on November 14, 2019

Class Action Claims Sanofi Knowingly Sold Zantac Contaminated with Probable Carcinogen

by Erin Shaak

Last Updated on November 20, 2019

Melillo v. Sanofi-Aventis U.S. LLC et al.

Filed: November 12, 2019 § 1:19-cv-06376

A proposed class action claims Sanofi knowingly manufactured and sold Zantac contaminated with the probable carcinogen N-Nitrosodimethylamine (NDMA).

Law(s)

State(s)

New York

Categories

Medical/Health

Case Spotlight

Hair Relaxer Lawsuits

ClassAction.org Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on November 20, 2019 — 4:42 PM

Erin Shaak

erin@classaction.org

Erin works primarily on ClassAction.org’s newswire, reporting on cases as they happen.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.